DE14172396T1 - Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester - Google Patents
Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester Download PDFInfo
- Publication number
- DE14172396T1 DE14172396T1 DE14172396.5T DE14172396T DE14172396T1 DE 14172396 T1 DE14172396 T1 DE 14172396T1 DE 14172396 T DE14172396 T DE 14172396T DE 14172396 T1 DE14172396 T1 DE 14172396T1
- Authority
- DE
- Germany
- Prior art keywords
- composition
- active ingredient
- autoimmune disease
- controlled release
- daily dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Pharmazeutische Zusammensetzung mit kontrollierter Freisetzung zur oralen Verwendung bestehend aus Dimethylfumarat als Wirkstoff, wobei die tägliche Dosierung zwischen 480 und 720 mg Wirkstoff verabreicht in einer bis drei Dosierungen liegt, wobei die Zusammensetzung zur Verwendung bei der Behandlung einer Autoimmunkrankheit ist, wobei die Autoimmunkrankheit ausgewählt ist aus: i. Polyarthritis ii. multipler Sklerose (MS), iii. juveniler Diabetes Mellitus, iv. Hashimoto-Thyreoiditis, v. Grave’s disease, vi. SLE (systemischem Lupus Erythematodes), vii. Sjögren Syndrom, viii. perniziöser Anämie, ix. chronisch aktiver (lupoider) Hepatitis, x. rheumatoider Arthritis (RA), xi. optischer Neuritis.
Claims (11)
- Pharmazeutische Zusammensetzung mit kontrollierter Freisetzung zur oralen Verwendung bestehend aus Dimethylfumarat als Wirkstoff, wobei die tägliche Dosierung zwischen 480 und 720 mg Wirkstoff verabreicht in einer bis drei Dosierungen liegt, wobei die Zusammensetzung zur Verwendung bei der Behandlung einer Autoimmunkrankheit ist, wobei die Autoimmunkrankheit ausgewählt ist aus: i. Polyarthritis ii. multipler Sklerose (MS), iii. juveniler Diabetes Mellitus, iv. Hashimoto-Thyreoiditis, v. Grave’s disease, vi. SLE (systemischem Lupus Erythematodes), vii. Sjögren Syndrom, viii. perniziöser Anämie, ix. chronisch aktiver (lupoider) Hepatitis, x. rheumatoider Arthritis (RA), xi. optischer Neuritis.
- Zusammensetzung nach Anspruch 1, welche eine Dosierungsform mit pH-kontrollierter Freisetzung ist.
- Zusammensetzung nach Anspruch 2, welche mit einer magensaftresistenten Beschichtung versehen ist.
- Zusammensetzung nach Anspruch 3, welche eine multipartikuläre Zusammensetzung ist und deren einzelne Einheiten mit einer magensaftresistenten Beschichtung versehen sind.
- Zusammensetzung nach Anspruch 1, wobei die tägliche Dosierung zwischen 480 und 600 mg Wirkstoff liegt.
- Zusammensetzung nach Anspruch 1, wobei die tägliche Dosierung zwischen 600 und 720 mg Wirkstoff liegt.
- Zusammensetzung nach Anspruch 1, wobei die tägliche Dosierung 480 mg Wirkstoff ist.
- Zusammensetzung nach Anspruch 1, wobei die Dosierungsform 120, 180 oder 240 mg Wirkstoff umfasst.
- Zusammensetzung nach Anspruch 1, wobei die Autoimmunkrankheit multiple Sklerose ist.
- Pharmazeutische Zusammensetzung mit kontrollierter Freisetzung zur oralen Verwendung bestehend aus Dimethylfumarat als Wirkstoff, wobei die tägliche Dosierung 480 mg Wirkstoff verabreicht in einer bis drei Dosierungen ist, wobei die Zusammensetzung zur Verwendung bei der Behandlung einer Autoimmunkrankheit ist, wobei die Autoimmunkrankheit ausgewählt ist aus: i. Polyarthritis ii. multipler Sklerose (MS), iii. juveliner Diabetes Mellitus Typ I, iv. Hashimoto-Thyreoiditis, v. Grave’s disease, vi. SLE (systemischem Lupus Erythematodes), vii. Sjögren Syndrom, viii. perniziöser Anämie, ix. chronisch aktiver (lupoider) Hepatitis, x. rheumatoider Arthritis (RA), xi. optischer Neuritis.
- Zusammensetzung nach Anspruch 10 zur Verwendung bei der Behandlung von multipler Sklerose.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200401546 | 2004-10-08 | ||
DK200401546 | 2004-10-08 | ||
DK200401736 | 2004-11-10 | ||
DKPA200401736 | 2004-11-10 | ||
DKPA200500211 | 2005-02-11 | ||
DK200500211 | 2005-02-11 | ||
DK200500419 | 2005-03-23 | ||
DKPA200500419 | 2005-03-23 | ||
US69151305P | 2005-06-16 | 2005-06-16 | |
US691513P | 2005-06-16 | ||
EP14172396.5A EP2792349A3 (de) | 2004-10-08 | 2005-10-07 | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
Publications (1)
Publication Number | Publication Date |
---|---|
DE14172396T1 true DE14172396T1 (de) | 2015-01-08 |
Family
ID=50726313
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE14172396.5T Pending DE14172396T1 (de) | 2004-10-08 | 2005-10-07 | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
DE14172398.1T Pending DE14172398T1 (de) | 2004-10-08 | 2005-10-07 | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
DE14172390.8T Pending DE14172390T1 (de) | 2004-10-08 | 2005-10-07 | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
DE202005022112.0U Expired - Lifetime DE202005022112U1 (de) | 2004-10-08 | 2005-10-07 | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE14172398.1T Pending DE14172398T1 (de) | 2004-10-08 | 2005-10-07 | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
DE14172390.8T Pending DE14172390T1 (de) | 2004-10-08 | 2005-10-07 | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
DE202005022112.0U Expired - Lifetime DE202005022112U1 (de) | 2004-10-08 | 2005-10-07 | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
Country Status (19)
Country | Link |
---|---|
US (29) | US20140099364A2 (de) |
EP (9) | EP2801355B1 (de) |
JP (5) | JP2008515822A (de) |
CY (5) | CY1113792T1 (de) |
DE (4) | DE14172396T1 (de) |
DK (4) | DK1799196T3 (de) |
ES (5) | ES2525497T3 (de) |
FR (1) | FR15C0074I2 (de) |
HK (1) | HK1108836A1 (de) |
HR (1) | HRP20170677T1 (de) |
HU (3) | HUE028342T2 (de) |
LT (2) | LT2801354T (de) |
LU (1) | LU92871I2 (de) |
ME (2) | ME02253B (de) |
PL (4) | PL2801354T3 (de) |
PT (4) | PT2801354T (de) |
RS (2) | RS55936B1 (de) |
SI (4) | SI1799196T1 (de) |
WO (1) | WO2006037342A2 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
AU2004269903B2 (en) | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
US20140099364A2 (en) * | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
US20080299196A1 (en) * | 2005-10-07 | 2008-12-04 | Aditech Pharma Ab | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester |
WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
US20070142905A1 (en) * | 2005-12-16 | 2007-06-21 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
CA2633167A1 (en) * | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
PL2046334T3 (pl) * | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
ES2916649T3 (es) | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Composiciones y usos para el tratamiento de la esclerosis múltiple |
US20100130607A1 (en) | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
EP2650279A3 (de) | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Methylwasserstoff-prodrugs, pharmazeutische zusammensetzungen daraus und anwendungsverfahren |
JP2012514623A (ja) * | 2009-01-09 | 2012-06-28 | フォーワード・ファルマ・アクティーゼルスカブ | 1またはそれ以上のフマル酸エステルを含む医薬組成物 |
PT2379063E (pt) | 2009-01-09 | 2013-05-03 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
HK1252751A1 (zh) * | 2009-01-09 | 2019-05-31 | Fwp Ip Aps | 包含溶蝕骨架中的一種或多種富馬酸酯的藥物製劑 |
EP3466420A1 (de) | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethylfumarat zur behandlung von friedreich-ataxie |
EP2533634B1 (de) | 2010-02-12 | 2015-10-21 | Biogen MA Inc. | Nervenschutz bei entmarkungserkrankungen |
EP2544667B1 (de) * | 2010-03-09 | 2018-11-14 | Alkermes Pharma Ireland Limited | Alkoholresistente enterale pharmazeutische zusammensetzungen |
AU2012238665B2 (en) * | 2011-04-08 | 2016-09-29 | Bracco Imaging Spa | Process for the preparation of a sulfated derivative of 3,5-diiodo-O-[3-iodophenyl]-L-tyrosine |
CN103649041A (zh) | 2011-06-08 | 2014-03-19 | 比奥根艾迪克Ma公司 | 制备高纯度和结晶的富马酸二甲酯的方法 |
EP2782561A1 (de) * | 2011-11-24 | 2014-10-01 | Synthon BV | Partikel mit gesteuerter freisetzung mit dimethylfumarat |
WO2013076216A1 (en) | 2011-11-24 | 2013-05-30 | Synthon Bv | Controlled release particles comprising dimethyl fumarate |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
CN114146080A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
US8952006B2 (en) | 2012-02-07 | 2015-02-10 | Xenoport, Inc. | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
WO2014031844A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
JP6506174B2 (ja) | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
RS57497B1 (sr) | 2013-03-14 | 2018-10-31 | Alkermes Pharma Ireland Ltd | Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
WO2015017762A1 (en) * | 2013-08-01 | 2015-02-05 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
EA201690107A1 (ru) * | 2013-08-26 | 2016-10-31 | Форвард Фарма А/С | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе |
TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | (n,n-二乙基胺甲醯基)甲基(2e)丁-2-烯-1,4-二酸甲酯之晶形、合成方法及用途 |
UA120428C2 (uk) * | 2013-12-12 | 2019-12-10 | Алміралл, С.А. | Фармацевтичні композиції, які містять диметилфумарат |
EP3079663A1 (de) | 2013-12-13 | 2016-10-19 | Biogen MA Inc. | Dosierungsform mit gesteuerter freisetzung zur einmal täglichen verabreichung von dimethylfumarat |
EP3110793B1 (de) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamid und sulfinamid-prodrugs von fumaraten und deren verwendung zur behandlung verschiedener erkrankungen |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
EP3501510B1 (de) | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Enterische weichkapseln von fumaratestern mit kontrollierter freisetzung |
EP3116536A1 (de) | 2014-03-14 | 2017-01-18 | Biogen MA Inc. | Dimethylfumarat und impfpläne |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
US20150298008A1 (en) * | 2014-04-16 | 2015-10-22 | Zynga Inc. | Systems and methods of incentivizing game play |
WO2016057133A1 (en) * | 2014-10-08 | 2016-04-14 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
MA41139A (fr) * | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
KR102283582B1 (ko) | 2014-12-23 | 2021-07-30 | 한미약품 주식회사 | 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제 |
WO2016113754A2 (en) * | 2015-01-14 | 2016-07-21 | Leiutis Pharmaceuticals Pvt, Ltd. | Novel oral dosage forms of dimethyl fumarate |
EA037666B1 (ru) * | 2015-02-08 | 2021-04-28 | Алкермес Фарма Айрленд Лимитед | Фармацевтическая композиция, содержащая 2-(2,5-диоксопирролидин-1-ил)этилметилфумарат, и ее применение в медицине |
EP3270911A4 (de) * | 2015-03-17 | 2018-08-29 | Hetero Labs Limited | Pharmazeutische zusammensetzungen von dimethylfumarat |
MA41785A (fr) * | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
WO2016194004A1 (en) * | 2015-06-01 | 2016-12-08 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical compositions of dimethyl fumarate |
MA42196A (fr) * | 2015-06-17 | 2018-04-25 | Biogen Ma Inc | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques |
US10213411B2 (en) | 2015-08-27 | 2019-02-26 | Vijaykumar Rajasekhar | Use of prodrugs of fumarates in treating heart failure diseases |
WO2017060400A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions |
EP3407873A1 (de) * | 2016-01-28 | 2018-12-05 | Zaklady Farmaceutyczne Polpharma SA | Verfahren zur herstellung eines granulats mit dimethylfumarat |
US10463642B2 (en) | 2016-02-01 | 2019-11-05 | Vijaykumar Rajasekhar | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate |
EP3413879A1 (de) * | 2016-02-11 | 2018-12-19 | Biogen MA Inc. | Pharmazeutische kornformulierungen mit dimethylfumarat |
CN110636838A (zh) * | 2017-06-23 | 2019-12-31 | 阿尔米雷尔有限公司 | 包含反丁烯二酸二甲酯的药物组合物 |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
RU2742745C1 (ru) * | 2019-09-24 | 2021-02-10 | Акционерное общество "Исследовательский Институт Химического Разнообразия" | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом |
WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
WO2021144478A2 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
IL307342A (en) | 2021-05-28 | 2023-11-01 | Amgen Inc | Formulations of Eframilest |
WO2023084320A1 (en) * | 2021-11-11 | 2023-05-19 | V-Ensure Pharma Technologies Private Limited | Reconstitutable, single use antidiabetic compositions |
US20240010618A1 (en) * | 2021-12-23 | 2024-01-11 | Glenmark Lofe Science Limited | Process for the preparation of brivaracetam |
CN116524199B (zh) * | 2023-04-23 | 2024-03-08 | 江苏大学 | 一种基于PReNet渐进式网络的图像去雨方法及装置 |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2764609A (en) * | 1953-07-24 | 1956-09-25 | Monsanto Chemicals | Isomerization of dialkyl maleates to dialkyl fumarates |
US3078302A (en) * | 1958-09-25 | 1963-02-19 | Monsanto Chemicals | Production of dialkyl fumarates |
GB1153927A (en) | 1966-08-25 | 1969-06-04 | Wilhelm Hoerrmann | Medicinal Composition Suitable For Treating Diseases Of The Retina |
US4952594A (en) * | 1973-06-18 | 1990-08-28 | Mercer James B | Reagents and method for therapeutic treatment of multiple sclerosis |
DE2703964A1 (de) | 1975-07-08 | 1978-08-03 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
DE2530372A1 (de) | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
US4145438A (en) * | 1975-09-10 | 1979-03-20 | Fisons Limited | Method for treatment of eczema or psoriasis |
DE2621214C3 (de) | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
DE2732131A1 (de) | 1977-07-15 | 1979-01-25 | Bayer Ag | Verfahren zur herstellung von seitenstaendige hydroxylgruppen aufweisenden isocyanat-polyadditionsprodukten |
DE2749188C2 (de) | 1977-11-03 | 1981-11-12 | Bayer Ag, 5090 Leverkusen | Vorrichtung zum automatischen Einführen eines schnellaufenden Fadens in einen Fadenführungskanal einer Fadenbehandlungsvorrichtung |
DE2840498C2 (de) | 1978-09-18 | 1980-04-10 | Walter Dr. 6700 Ludwigshafen Schweckendiek | Pharmazeutische Zubereitungen zur Behandlung von Psoriasis |
US4302440B1 (en) * | 1980-07-31 | 1986-08-05 | Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof | |
US5149695A (en) * | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
US4693896A (en) | 1985-10-07 | 1987-09-15 | Fmc Corporation | Ethylcellulose-coated, gastric-disintegrable aspirin tablet |
US4855305A (en) | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
DE3711155A1 (de) * | 1987-04-02 | 1988-10-13 | Bayer Ag | Verfahren zur herstellung von maleinsaeuredimethylester |
IL83775A (en) | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
US5214196A (en) * | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
US5424332A (en) * | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
US5023245A (en) * | 1987-11-10 | 1991-06-11 | Hauser-Kuhrts, Inc. | Improved niacin formulation |
US4965252A (en) | 1988-06-28 | 1990-10-23 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination compositions of guar gum and niacin |
US4911917A (en) * | 1988-06-28 | 1990-03-27 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination comopsitions of magnesium salt and niacin |
DE3834794A1 (de) | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
US5484610A (en) | 1991-01-02 | 1996-01-16 | Macromed, Inc. | pH and temperature sensitive terpolymers for oral drug delivery |
GEP19971086B (en) | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
US5246947A (en) * | 1991-09-23 | 1993-09-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression |
FR2694693B1 (fr) | 1992-07-28 | 1994-10-28 | Abrax Bio Labs Sa | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. |
DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
US5434185A (en) | 1993-05-17 | 1995-07-18 | The University Of Kentucky Research Foundation | Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts |
CN1096862C (zh) | 1994-05-06 | 2002-12-25 | 辉瑞大药厂 | 阿齐霉素的控释剂型 |
US5589504A (en) * | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US6139850A (en) * | 1994-12-21 | 2000-10-31 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5804203A (en) * | 1994-12-21 | 1998-09-08 | Cosmederm Technologies | Topical product formulations containing strontium for reducing skin irritation |
EP0737471A3 (de) * | 1995-04-10 | 2000-12-06 | L'oreal | Verwendung von Erdalkalimetallsalze als TNF-alpha Inhibitor in einer topischen Zusammensetzung und die so hergestellte Zusammensetzung |
AU5787996A (en) | 1995-04-19 | 1996-11-07 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
JP2001527517A (ja) | 1996-07-26 | 2001-12-25 | スーザン・ピー・ペリーネ | 血液、ウイルス性および細胞性疾患の治療組成物 |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
NZ333474A (en) * | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
DE69804865T2 (de) | 1998-01-22 | 2002-11-07 | Zentaris Ag | Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis |
DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
CA2327685C (en) * | 1998-04-03 | 2008-11-18 | Bm Research A/S | Controlled release composition |
US20050220909A1 (en) * | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
KR100297705B1 (ko) * | 1999-03-29 | 2001-10-29 | 김덕중 | 낮은 온저항과 높은 항복전압을 갖는 전력용 반도체소자 |
US6537584B1 (en) | 1999-11-12 | 2003-03-25 | Macromed, Inc. | Polymer blends that swell in an acidic environment and deswell in a basic environment |
DE10000577A1 (de) * | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
EP1176136A4 (de) * | 2000-02-15 | 2005-12-07 | Showa Denko Kk | Verfahren zur herstellung von fumarsäureester |
AU3846801A (en) * | 2000-02-16 | 2001-08-27 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
IT1317042B1 (it) * | 2000-06-14 | 2003-05-26 | Biosalts Srl | Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono. |
EP1172101A1 (de) * | 2000-06-20 | 2002-01-16 | Helsinn Healthcare S.A. | Verwendung von Nimesulfid zur Behandlung von Psoriasis und psoriatischer Arthritis |
WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
WO2002032374A2 (en) * | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
WO2002055063A2 (de) * | 2001-01-12 | 2002-07-18 | Fumapharm Ag | Fumarsäureamide |
SE0100200D0 (sv) | 2001-01-24 | 2001-01-24 | Astrazeneca Ab | New film coating |
RU2330642C2 (ru) | 2001-07-06 | 2008-08-10 | Лайфсайкл Фарма А/С | Регулируемая агломерация |
NO20014746D0 (no) | 2001-09-28 | 2001-09-28 | Clas M Kjoelberg | Smertelindrende middel |
TWI239520B (en) * | 2001-10-12 | 2005-09-11 | Konica Corp | Objective lens, optical element, optical pick-up apparatus and optical information recording and/or reproducing apparatus equipped therewith |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
CN1615135A (zh) | 2001-11-13 | 2005-05-11 | 法马西亚公司 | 磺酰胺前药如帕瑞考昔的口服剂型 |
US6613800B1 (en) * | 2001-12-03 | 2003-09-02 | Steven A. Smith | Method and compositions for treating psoriasis, eczema, seborrhea and arthritis |
KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
US20030203055A1 (en) | 2002-03-15 | 2003-10-30 | Cypress Bioscience, Inc. | Methods of treating visceral pain syndromes |
DE10214031A1 (de) | 2002-03-27 | 2004-02-19 | Pharmatech Gmbh | Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation |
US20030185915A1 (en) * | 2002-03-28 | 2003-10-02 | Jaime Carlo | Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor |
DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
US20030219456A1 (en) * | 2002-05-21 | 2003-11-27 | Taing Ok | Method of utilization of zygosaccharomyces rouxii |
US6830759B2 (en) | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
JP2006500372A (ja) | 2002-08-19 | 2006-01-05 | グラクソ グループ リミテッド | 選択的cox−2阻害物質としてのピリミジン誘導体 |
WO2004084920A2 (en) | 2003-03-27 | 2004-10-07 | Santosolve As | Anti-inflammatory treatment based on strontium compounds |
AU2004237439B2 (en) | 2003-05-07 | 2009-09-10 | Osteologix A/S | Treating cartilage/bone conditions with water-soluble strontium salts |
CA2524610C (en) | 2003-05-07 | 2014-03-25 | Osteologix A/S | Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions |
PL1622629T3 (pl) | 2003-05-07 | 2013-12-31 | Osteologix As | Kompozycja do kontrolowanego uwalniania zawierająca sól strontu |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
AP1899A (en) | 2003-08-08 | 2008-10-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
AU2004269903B2 (en) * | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
WO2005097082A1 (en) | 2004-03-31 | 2005-10-20 | Bpsi Holdings, Inc. | Enteric coatings for orally ingestible substrates |
TW200603792A (en) | 2004-04-23 | 2006-02-01 | Pharmacia & Upjohn Co Llc | Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors |
CN1245873C (zh) | 2004-08-21 | 2006-03-22 | 王立峰 | 富马酸二甲酯微胶囊及其制备方法 |
US20140099364A2 (en) | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
CN101056624A (zh) | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
US20080004344A1 (en) * | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
WO2006050730A1 (en) | 2004-11-10 | 2006-05-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
DE102005022845A1 (de) * | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
US20070071819A1 (en) * | 2005-05-30 | 2007-03-29 | Kesarwani Amit K | Multiple unit modified release compositions of carbamazepine and process for their preparation |
WO2007005879A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
ATE455783T1 (de) * | 2005-07-07 | 2010-02-15 | Aditech Pharma Ag | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung |
WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
US20080299196A1 (en) * | 2005-10-07 | 2008-12-04 | Aditech Pharma Ab | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester |
JP5232658B2 (ja) * | 2006-02-15 | 2013-07-10 | エムディー バイオアルファ カンパニー リミテッド | オキシドレダクターゼによるnad(p)/nad(p)h比を制御するための方法 |
WO2007148744A1 (ja) | 2006-06-21 | 2007-12-27 | Santen Pharmaceutical Co., Ltd. | フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤 |
MX2009002299A (es) | 2006-09-01 | 2009-03-20 | Cv Therapeutics Inc | Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio. |
US20100130607A1 (en) | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
ES2916649T3 (es) * | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Composiciones y usos para el tratamiento de la esclerosis múltiple |
WO2008129698A1 (ja) | 2007-04-12 | 2008-10-30 | Panasonic Corporation | 電源システムおよび組電池の充電方法 |
MX2009011493A (es) | 2007-04-25 | 2009-11-09 | Teva Pharma | Complejo de excipiente farmaceutico. |
US20080274182A1 (en) | 2007-05-03 | 2008-11-06 | Regina Helena Alida Boekema | Tablet coatings made from modified carboxymethylcellulose materials |
WO2009005803A1 (en) | 2007-07-01 | 2009-01-08 | Joseph Peter Habboushe | Combination tablet with chewable outer layer |
KR20090028047A (ko) * | 2007-09-13 | 2009-03-18 | 경북대학교 산학협력단 | 디메틸푸마레이트의 신규 용도 |
CN101318901A (zh) | 2008-06-17 | 2008-12-10 | 健雄职业技术学院 | 一种富马酸二甲酯的合成新工艺 |
EP2650279A3 (de) * | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Methylwasserstoff-prodrugs, pharmazeutische zusammensetzungen daraus und anwendungsverfahren |
PT2379063E (pt) | 2009-01-09 | 2013-05-03 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
JP2012514623A (ja) | 2009-01-09 | 2012-06-28 | フォーワード・ファルマ・アクティーゼルスカブ | 1またはそれ以上のフマル酸エステルを含む医薬組成物 |
CN101475477A (zh) | 2009-01-23 | 2009-07-08 | 上海化学试剂研究所 | 反丁烯二酸二甲酯的制备方法 |
WO2010113096A1 (en) * | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
EP3466420A1 (de) | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethylfumarat zur behandlung von friedreich-ataxie |
CN101701943A (zh) | 2009-11-05 | 2010-05-05 | 宁波中普检测技术服务有限公司 | 气相色谱-质谱联用测定产品中富马酸二甲酯的方法 |
EP2533634B1 (de) | 2010-02-12 | 2015-10-21 | Biogen MA Inc. | Nervenschutz bei entmarkungserkrankungen |
US20140163100A1 (en) | 2011-05-26 | 2014-06-12 | Biogen Idec Ma Inc. | Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content |
CN103649041A (zh) | 2011-06-08 | 2014-03-19 | 比奥根艾迪克Ma公司 | 制备高纯度和结晶的富马酸二甲酯的方法 |
WO2013076216A1 (en) | 2011-11-24 | 2013-05-30 | Synthon Bv | Controlled release particles comprising dimethyl fumarate |
CN114146080A (zh) | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
WO2014031844A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
KR102092289B1 (ko) * | 2013-06-03 | 2020-03-23 | 삼성전자주식회사 | 전자 기기 및 이의 문서 작성 방법 |
EP3079663A1 (de) | 2013-12-13 | 2016-10-19 | Biogen MA Inc. | Dosierungsform mit gesteuerter freisetzung zur einmal täglichen verabreichung von dimethylfumarat |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
EP3501510B1 (de) | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Enterische weichkapseln von fumaratestern mit kontrollierter freisetzung |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
WO2016057133A1 (en) | 2014-10-08 | 2016-04-14 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
WO2017040272A1 (en) | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
WO2017151184A1 (en) | 2016-02-29 | 2017-09-08 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US10523918B2 (en) | 2017-03-24 | 2019-12-31 | Samsung Electronics Co., Ltd. | System and method for depth map |
-
2005
- 2005-10-07 US US11/576,871 patent/US20140099364A2/en not_active Abandoned
- 2005-10-07 EP EP20140172398 patent/EP2801355B1/de not_active Revoked
- 2005-10-07 WO PCT/DK2005/000648 patent/WO2006037342A2/en active Search and Examination
- 2005-10-07 PL PL14172390T patent/PL2801354T3/pl unknown
- 2005-10-07 EP EP16001391.8A patent/EP3093012A1/de not_active Withdrawn
- 2005-10-07 SI SI200532086A patent/SI1799196T1/sl unknown
- 2005-10-07 SI SI200532146A patent/SI2801354T1/sl unknown
- 2005-10-07 PL PL05789026.1T patent/PL1799196T3/pl unknown
- 2005-10-07 ES ES14172398.1T patent/ES2525497T3/es active Active
- 2005-10-07 PT PT141723908T patent/PT2801354T/pt unknown
- 2005-10-07 ES ES10182198T patent/ES2387192T3/es active Active
- 2005-10-07 ME MEP-2015-540A patent/ME02253B/de unknown
- 2005-10-07 DK DK05789026.1T patent/DK1799196T3/en active
- 2005-10-07 ES ES05789026.1T patent/ES2582942T3/es active Active
- 2005-10-07 EP EP05789026.1A patent/EP1799196B1/de not_active Revoked
- 2005-10-07 PT PT57890261T patent/PT1799196T/pt unknown
- 2005-10-07 DK DK10182198.1T patent/DK2316430T3/da active
- 2005-10-07 ES ES14172396.5T patent/ES2523796T1/es active Pending
- 2005-10-07 RS RS20170452A patent/RS55936B1/sr unknown
- 2005-10-07 PL PL10182198T patent/PL2316430T3/pl unknown
- 2005-10-07 DE DE14172396.5T patent/DE14172396T1/de active Pending
- 2005-10-07 PT PT10182198T patent/PT2316430E/pt unknown
- 2005-10-07 DE DE14172398.1T patent/DE14172398T1/de active Pending
- 2005-10-07 DE DE14172390.8T patent/DE14172390T1/de active Pending
- 2005-10-07 HU HUE05789026A patent/HUE028342T2/en unknown
- 2005-10-07 ES ES14172390.8T patent/ES2525495T3/es active Active
- 2005-10-07 HU HUE14172390A patent/HUE031950T2/en unknown
- 2005-10-07 RS RS20150540A patent/RS54187B1/en unknown
- 2005-10-07 JP JP2007535023A patent/JP2008515822A/ja active Pending
- 2005-10-07 EP EP14172390.8A patent/EP2801354B1/de not_active Revoked
- 2005-10-07 DE DE202005022112.0U patent/DE202005022112U1/de not_active Expired - Lifetime
- 2005-10-07 EP EP14172396.5A patent/EP2792349A3/de not_active Ceased
- 2005-10-07 LT LTEP14172390.8T patent/LT2801354T/lt unknown
- 2005-10-07 PT PT141723981T patent/PT2801355E/pt unknown
- 2005-10-07 DK DK14172398.1T patent/DK2801355T3/en active
- 2005-10-07 SI SI200531565T patent/SI2316430T1/sl unknown
- 2005-10-07 PL PL14172398T patent/PL2801355T3/pl unknown
- 2005-10-07 EP EP15166243.4A patent/EP2965751A1/de not_active Withdrawn
- 2005-10-07 ME MEP-2017-102A patent/ME02746B/de unknown
- 2005-10-07 DK DK14172390.8T patent/DK2801354T3/en active
- 2005-10-07 EP EP10182198A patent/EP2316430B8/de not_active Revoked
- 2005-10-07 LT LTEP05789026.1T patent/LT1799196T/lt unknown
- 2005-10-07 SI SI200531993T patent/SI2801355T1/sl unknown
- 2005-10-07 EP EP18204738.1A patent/EP3459532A1/de not_active Withdrawn
- 2005-10-07 EP EP18208053.1A patent/EP3470064A1/de not_active Withdrawn
-
2007
- 2007-12-24 HK HK07114067.2A patent/HK1108836A1/zh not_active IP Right Cessation
-
2012
- 2012-08-16 CY CY20121100740T patent/CY1113792T1/el unknown
- 2012-12-06 JP JP2012267572A patent/JP2013064007A/ja active Pending
-
2013
- 2013-08-01 US US13/957,117 patent/US20140037720A1/en not_active Abandoned
- 2013-08-01 US US13/957,220 patent/US20130316003A1/en not_active Abandoned
- 2013-08-01 US US13/957,250 patent/US20140037740A1/en not_active Abandoned
- 2013-08-01 US US13/957,147 patent/US20130315993A1/en not_active Abandoned
-
2014
- 2014-03-13 US US14/209,651 patent/US20140200273A1/en not_active Abandoned
- 2014-03-13 US US14/209,712 patent/US20140199386A1/en not_active Abandoned
- 2014-03-13 US US14/209,584 patent/US20140200272A1/en not_active Abandoned
- 2014-03-13 US US14/209,480 patent/US20170112793A2/en not_active Abandoned
- 2014-03-13 US US14/209,756 patent/US20140199393A1/en not_active Abandoned
- 2014-03-13 US US14/209,823 patent/US20150024049A1/en not_active Abandoned
- 2014-03-14 US US14/213,321 patent/US20140199387A1/en not_active Abandoned
- 2014-03-14 US US14/213,399 patent/US20140205659A1/en not_active Abandoned
- 2014-03-14 US US14/212,685 patent/US20140199392A1/en not_active Abandoned
- 2014-03-14 US US14/212,503 patent/US20140199390A1/en not_active Abandoned
- 2014-03-14 US US14/213,673 patent/US20140199388A1/en not_active Abandoned
-
2015
- 2015-07-13 JP JP2015139809A patent/JP2015227350A/ja active Pending
- 2015-08-04 CY CY20151100679T patent/CY1116599T1/el unknown
- 2015-11-09 FR FR15C0074C patent/FR15C0074I2/fr active Active
- 2015-11-13 LU LU92871C patent/LU92871I2/xx unknown
- 2015-11-18 HU HUS1500057C patent/HUS1500057I1/hu unknown
- 2015-11-19 CY CY2015045C patent/CY2015045I2/el unknown
-
2016
- 2016-08-30 CY CY20161100847T patent/CY1117937T1/el unknown
-
2017
- 2017-04-28 US US15/581,966 patent/US20170231941A1/en not_active Abandoned
- 2017-05-04 HR HRP20170677TT patent/HRP20170677T1/hr unknown
- 2017-05-08 CY CY20171100493T patent/CY1118887T1/el unknown
- 2017-10-10 US US15/728,872 patent/US20180028483A1/en not_active Abandoned
- 2017-12-07 US US15/834,870 patent/US20180098957A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017332A patent/JP2018087220A/ja active Pending
- 2018-05-24 US US15/988,628 patent/US20180263947A1/en not_active Abandoned
- 2018-07-26 US US16/046,509 patent/US20180325855A1/en not_active Abandoned
- 2018-11-29 US US16/204,503 patent/US20190091192A1/en not_active Abandoned
- 2018-11-29 US US16/204,403 patent/US20190091191A1/en not_active Abandoned
- 2018-11-29 US US16/204,559 patent/US20190091193A1/en not_active Abandoned
- 2018-12-20 US US16/227,287 patent/US11229619B2/en active Active
-
2019
- 2019-03-06 US US16/294,038 patent/US20190201368A1/en not_active Abandoned
- 2019-05-20 JP JP2019094350A patent/JP6896792B2/ja active Active
- 2019-07-29 US US16/525,392 patent/US11052062B2/en active Active
-
2021
- 2021-02-25 US US17/185,600 patent/US20210220318A1/en not_active Abandoned
- 2021-12-16 US US17/553,367 patent/US20220105064A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE14172396T1 (de) | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester | |
Parkes et al. | Controlled trial of amantadine hydrochloride in Parkinson's disease | |
KR930700112A (ko) | 다관능성 약학적 화합물 및 이의 사용방법 | |
NO924169D0 (no) | Preparat omfattende et tramadolmateriale og et ikke-stereoid antiinflammatorisk legemiddel | |
DE236684T1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
DE69840909D1 (de) | Analoge von kokain | |
NO305932B1 (no) | Farmasoeytisk akseptabel L-DOPA-etylesterbase, et farmasoeytisk preparat innneholdende base, en fremgangsmåte for fremstilling av preparatet samt L-DOPA-etylesteren | |
JP2002520277A (ja) | 不眠症を治療する方法 | |
HK1061357A1 (en) | Fibrate-statin combinations with reduced fed-fasted effects | |
DE29909211U1 (de) | Neue Effektoren von Dipeptidylpeptidase IV | |
DE69628163D1 (de) | Nor-pregnane zur induzierung hypothalamischer effekte | |
KR970705553A (ko) | 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents) | |
DK616186D0 (da) | Farmaceutisk praeparat med retarderet frigivelse af ibuprofen | |
ATE206914T1 (de) | Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen | |
DE59206675D1 (de) | Ein ibuprofen enthaltendes akut-arzneimittel und seine verwendung | |
BRPI0416882A (pt) | composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
KR890015739A (ko) | 인터루킨-1 생합성 억제제인 3-치환된-2-옥신돌-1-카복사미드 | |
KR940013503A (ko) | 동맥경화증의 예방 또는 치료용 약제학적 조성물 | |
DE706395T1 (de) | Verwendung von ropivacaine zur herstellung eines analgetikmus mit minimaler motorischer blockade | |
KR970005283A (ko) | 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도 | |
JP2002520300A (ja) | Gaba類縁体及び抗ウイルス剤を含んでなる帯状ヘルペスを治療するための医薬組成物 | |
DE50202865D1 (de) | Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
KR910007526A (ko) | 인터류킨-1 생합성 억제제로의 3-치화된-2-옥신돌 유도체 | |
RU93004536A (ru) | Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя |